Analysis of Human RSV Immunity at the Molecular Level: Learning from the Past and Present

Kerrie Vaughan1*, Julia Ponomarenko2, Bjoern Peters1, Alessandro Sette1

1 La Jolla Institute for Allergy and Immunology, La Jolla, California, United States of America, 2 San Diego Supercomputer Center, University of California San Diego, La Jolla, California, United States of America

* kvaughan@liai.org

Abstract

Human RSV is one of the most prevalent viral pathogens of early childhood for which no vaccine is available. Herein we provide an analysis of RSV epitope data to examine its application to vaccine design and development. Our objective was to provide an overview of antigenic coverage, identify critical antibody and T cell determinants, and then analyze the cumulative RSV epitope data from the standpoint of functional responses using a combinational approach to characterize antigenic structure and epitope location. A review of the cumulative data revealed, not surprisingly, that the vast majority of epitopes have been defined for the two major surface antigens, F and G. Antibody and T cell determinants have been reported from multiple hosts, including those from human subjects following natural infection, however human data represent a minority of the data. A structural analysis of the major surface antigen, F, showed that the majority of epitopes defined for functional antibodies (neutralizing and/or protective) were either shown to bind pre-F or to be accessible in both pre- and post-F forms. This finding may have implications for on-going vaccine design and development. These interpretations are in agreement with previous work and can be applied in the larger context of functional epitopes on the F protein. It is our hope that this work will provide the basis for further RSV-specific epitope discovery and investigation into the nature of antigen conformation in immunogenicity.

Introduction

Despite the fact that viral pathogenesis and immunity to RSV are well characterized in humans and in animal models of disease [1–4], human respiratory syncytial virus (HRSV) is one of the most prevalent viral pathogens of early childhood for which no vaccine is available. In the 1960s, a formalin-inactivated (FI-RSV) vaccine candidate failed to provide protection and was associated with enhanced disease [5]. As a result, subsequent research focused on elucidating the underlying mechanisms of disease enhancement and clarifying correlates of protection to ensure that future vaccine candidates would be uniformly effective.
It is believed that FI-RSV vaccine enhanced disease was a result of the alteration of critical epitopes as a result of formalin inactivation [6–9]. The generation of non-neutralizing and non-fusion inhibiting antibodies and the predominance of an inflammatory CD4+ T cell-driven Th2 cytokine response [10–12] have been shown to play roles in disease exacerbation. Indeed, chemical alteration of epitopes has been implicated in immune responses to several vaccine candidates, including measles [13, 14], influenza A [15] and pertussis [16, 17]. Understanding the molecular mechanisms of protection and disease exacerbation in the context of both humoral and cellular responses helps guide current efforts towards vaccine development.

Several groups are pursuing novel approaches for RSV vaccine design that incorporate epitope- and structure-based methods [18–21]. These approaches focus on the fusion protein (F), a major target of neutralizing antibodies [8, 22]. The F protein is a prominent surface glycoprotein that mediates viral attachment, penetration and viral spread. During infection, F undergoes significant processing, structural and conformational changes. The translated F0 precursor is cleaved into two disulfide-linked chains, F2 and F1 [23, 24]. The F protein exists in vivo in two configurations: a globular pre-fusion (pre-F) form present in virus particles [25], which is triggered upon binding to the host cell to refold into an elongated post-fusion (post-F) form. It is believed that the pre-fusion form is a major target of neutralizing antibody activity [26]. However well-known monoclonal antibodies used prophylactically in humans [e.g. Palivizumab (Synagis)] have been shown to bind the post-fusion F protein [18, 27]. This is explained by the fact that some antibody epitopes remain accessible and unchanged in both pre- and post-F fusion forms [19, 28].

Our aim was to use the data and tools housed in the Immune Epitope Database (IEDB) and Analysis resource [www.epitope.org] to comprehensively analyze all antibody/B cell and T cell epitopes described to date for the F protein. We used a combination of in silico prediction tools housed at the IEDB and other computational methods to characterize the nature and structural features of these epitopes on available 3D structures of the F protein and then compared these results to known (experimentally derived) functional/protective sites. We found that the majority of epitopes defined for functional antibodies was either shown to bind pre-F or to be solvent accessible in both pre- and post-F forms. Finally, we observed an alignment of functional B and T cell epitopes mapped along the length of the F protein, which might suggest a relationship between the location of epitopes and protein functional sites. These findings are in agreement with previous works [18–20] and can be applied in the larger context of all reported functional epitopes on the RSV F protein.

**Materials and Methods**

**Data Queries to the IEDB**

All queries were performed using the Immune Epitope Database and Analysis Resource (IEDB) home page search interface [www.iedb.org]. For more complex queries the advanced search interface (all fields) was utilized. Results were downloaded in Excel format for detailed analysis. Excel spreadsheets containing all B and T cell assay data were used to identify epitope sequence and source, assay type, immunization details, antibody isotype, effector cells (CD4/CD8), host, etc. RSV-specific queries were conducted using the Antigen organism finder, using the input ‘Pneumovirus.’ In the IEDB, this genus currently includes human RSV (HRSV, RSV), bovine RSV (BRSV) and Ovine RSV (ORSV). The latter strains are used as animal models of natural infection and the viruses are antigenically homologous. Antigen-specific queries were performed using Antigen Finder or through analysis of above spreadsheets for response-association. Unless otherwise indicated, all reported data herein represent positive epitopes and/or assays only.
Nature and scope of assays defining epitopes

The IEDB defines an epitope the unique molecular structures (minimal sequences, linear and discontinuous regions, as well as key residues) experimentally shown to react with a B cell or T cell (no predictions). This includes peptides less than or equal to 50 amino acids in size and non-peptidic structures less than or equal to 5000 Daltons. These structures must be experimentally tested for binding to an adaptive immune receptor (T cell receptor (TCR), antibody or B cell receptor (BCR), or major histocompatibility complex (MHC)) or the receptor must be known and stated to be epitope specific in order to be included in the IEDB. Positive epitopes are defined as those residues or structures shown to bind in at least one positive assay; negative data (residues shown to be non-binding) are also captured in the IEDB. With respect to assay type, B cell/antibody assays considered herein to define ‘functional epitopes’ (Table 1) include,

Table 1. Linear B cell epitopes associated with virus neutralization or in vivo protection.

| Epitope          | Residues | Source      | Antibody | Assay | Assay Ag | PMID       |
|------------------|----------|-------------|----------|-------|----------|------------|
| SKPTTKQRQNKPPNK  | 144–159  | G HRSV Long, A2 | PC       | Prot, VN | Long<sup>x</sup> | 11257359, 1720589 |
| QNKPPKNPNNDF     | 152–163  | G HRSV Long  | 5C2 (lgG1) | Prot<sup>(PT)</sup> | Long | 11257359 |
| HFEVFNFVPCSIC    | 164–176  | G HRSV Long  | PC       | Prot | Long | 11257359 |
| FEVFNFVP         | 165–172  | G HRSV Long  | 5B7 (lgG1) | Prot<sup>(PT)</sup> | Long | 11257359 |
| FVPCSICSNNPTCAW  | 170–190  | G HRSV A2   | PC       | Prot | A2 | 11053254 |
| VPCSICSNNPTCAW   | 171–187  | G HRSV Long  | PC;18D1  | Prot<sup>(PT)</sup> | Long, RSV B 8/60<sup>x</sup> | 9141214, 11257359 |
| PCSICSNNPTCAW    | 172–187  | G HRSV      | PC       | Prot | HRSV | 11053254 |
| CSICSNNPTCAW     | 173–187  | G HRSV Long  | PC       | Prot | Long | 9234952 |
| STCEGNLACSL      | 174–185  | G BRSV Snook | PC       | Prot | BRSV (Ni) | 23890818 |
| KRIPNPKPGKKTTH   | 187–200  | G HRSV Long  | PC       | Prot | VN | 1383397 |
| PNKPKGKTHTKPT    | 190–204  | G HRSV Long  | MS       | Prot<sup>(PT)</sup> | Long | 11257359 |
| KTTTTPKTP        | 196–204  | G HRSV Long  | 8A3      | Prot<sup>(PT)</sup> | Long | 11257359 |
| IPELIHYTRNSTKRFY  | 111–148  | F BRSV (RB94) | PC       | Prot | BRSV (Ni) | 23890818 |
| LSMGWMLGKRRFLGFL | 174–187  | G HRSV Long  | PC       | Prot | Long | 9234952 |
| PCSICSNNPTCAW    | 172–187  | G HRSV      | PC       | Prot | HRSV | 11053254 |
| CSICSNNPTCAW     | 173–187  | G HRSV Long  | PC       | Prot | Long | 9234952 |
| STNCVAVSLS       | 173–182  | F BRSV (RB94) | 3        | VN | BRSV Lelystad<sup>x</sup> | 9541615 |
| PIVNQOCSISNIET    | 205–225  | F HRSV Long, A2; F HRSV B (18537) | PC | VN | Long, HRSV B<sup>x</sup> (18537); HRSV 9320 | 2033389, 7685537, 9228999 |
| TSTNTKGNLRLEITRF | 221–237  | F HRSV A2   | PC       | Prot | A2 | 1706591 |
| STYMLTNSELLSLINDMPTNDQKKLMSN  | 248–283  | F HRSV      | Motavizumab | VN | A2 | 20943340 |
| TNLMSNQVQRQ      | 262–283  | F HRSV      | Motavizumab | VN | A2 | 20098425, 23618766 |
| NSELLSLINDMPTNDQKKLMSNN | 254–277  | F HRSV A2   | Motavizumab | VN | A2 | 20098425, 23618766 |
| SELSLINDMPTNDQKKLMSNNV | 255–278  | F HRSV Long  | PC       | VN, Prot | Long | 17603843, 7685537 |
| TASNKRRGIKTFS    | 423–436  | F HRSV A2   | ch101F<sup>^</sup> | VN | A2 | 17872524 |
| KNRRGIKTFSN      | 427–437  | F HRSV A2   | 101F (lgG2a) | VN | A2 | 20881049, 23618766 |

PT, passive transfer
<sup>x</sup>, shows cross-protection; PC, polyclonal; VN, virus neutralization; Prot, in vivo challenge/survival; NI, natural infection
<sup>^</sup>ch101F is a mouse-human chimeric of 101F; Motavizumab is also a mouse-human chimera; all others are mouse; A2, HRSV A2 strain; Long, HRSV long strain

doi:10.1371/journal.pone.0127108.t001
in vitro neutralization (microneutralization or plaque reduction), and in vivo protection assays whereby epitope immunization is shown to increase survival or protection (decreased symptoms or viral load) following live viral challenge in an animal model. T cell assays considered to define functional epitopes include in vivo protection as described above, and those assays demonstrating in vitro cytotoxicity [51 chromium release or non-radioactive assay] showing epitope-specific killing of target cells, as well as in vitro cytokine production [ELISPOT, ELISA, and flow cytometry], wherein peripheral blood mononuclear cells (PBMCs) or lymphocytes are stimulated with or respond to the epitope as assay antigen.

Also of note with respect to the source of the data presented herein, discontinuous epitopes (non-linear/conformational) were most frequently defined using virus escape mutants whereby the alteration or substitution of critical residues conferred escape from in vitro neutralization in a standard microneutralization assay. Epitopes captured to date were also defined by crystallographic analysis of antigen-antibody complexes (x-ray crystallography) [PDBs: 3IXT, 3QWO, 4JLR (motavizumab), 4JHW (D25), 4N9G (17HD9), 3O41, 3O45 (101F)].

Pre- and Post-fusion Structures Analysis

For direct comparisons of antibody epitope prediction scores, Protein Data Bank (PDB) [www.rcsb.org/pdb] structures for the pre-F [PDB: 4HJW, 4MMS] and post-F [PDB: 3RKI, 3RRR] conformations were used. Separate chains comprising the trimeric structure of the F protein were re-worked manually into a single chain, which was used as input for the B cell epitope prediction tools, ElliPro [29] and Discotope (available on IEDB) [30, 31], both housed in the IEDB. Residue solvent accessibility in the structures was calculated with NACCESS [32]. We considered relative solvent accessibility (RSA) for side-chain atoms. Residue evolutionary conservation was calculated with the ConSurf server [33], using the multiple sequence alignment (MSA) generously provided by Dr. Jason S. McLellan [19].

For each predicted epitope in each protein, we calculated the correctly (true positive) and incorrectly predicted epitope residues (false positive) and non-epitope residues, which were defined as all other protein residues (true negative and false positive). The statistical significance of a prediction, that is, the difference between observed and expected frequencies of an actual epitope/non-epitope residue in the predicted epitope/non-epitope, was determined using the Fisher’s exact test. The prediction was considered significant if p-value was <= 0.05.

Immunome Browser and Homology Mapping Tool

The Immunome Browser (IB) is tool available on the IEDB website that allows users to visualize the relative prominence of antibody and T cell epitopes on their derivative antigens. The IB plots the response frequency score for each residues of an existing epitope onto an antigen or reference proteome. The response frequency score (RFscore) is calculated as (responded-square root (responded))/tested, where “tested” and “responded” correspond to numbers of individuals tested and responded to a given residue. The score has a range [0 to 1], and a higher score indicates that a larger fraction of individuals responded. The square root is a correction factor, approximating one standard deviation for the number of responding donors. This gives a higher score to epitopes studied with larger sample sizes. [34]. Thus, the tool allows visualizing those regions on the antigen(s) that are more immunodominant or more frequently studied in a given population for a particular response (Ab, T, CD4, CD8, etc.). This provides the least biased way to analyze the cumulative data and compare immune response among hosts, disease states, and assay types; for example, neutralization assays versus protection assays.
Homology Mapping

The Homology Mapping tool can be accessed at http://tools.immuneepitope.org/esm/userMappingFrontP.jsp or through the IEDB Analysis Tools menu. This tool uses input from the user (epitope residues or epitope ID) to map individual or a group of epitopes onto the three dimensional structure of the source protein provided by entering a SWISS-PROT, GenBank ID or FASTA. JAVA version 7 is required for this application.

Results

Summary of RSV immune epitope data

To determine the breadth of RSV-specific data available in the IEDB, we performed a broad query to enumerate all data reported from viruses within the genus *Pneumovirus*. As of January 2015, the IEDB contained 140 references describing 672 epitopes derived from this genus, including human RSV (567), bovine RSV (86), murine pneumonia virus (19) and ovine RSV (1) [number in parentheses means total epitopes for each virus]. These data include antibody/B cell (243) and T cell (323) epitopes, as well as epitopes naturally-eluted from human MHC-peptide complexes and those tested in MHC binding assays (160). Of the B cell epitopes, linear epitopes (208) vastly outnumbered discontinuous (35). For T cell epitopes, the majority have been described for class II/CD4\(^+\) (206) compared to class I/CD8\(^+\) (97). Thus the majority of reported data were from human RSV, representing a fairly broad range of immune reactivities, including all those within the broad categories of assay types: binding assays (e.g., ELISA), functional assays (e.g., neutralization, CTL) and *in vivo* challenge assays. Of the total T and B cell epitopes reported to date, 214 epitopes (32%) have been defined in humans. Non-human animal models used in the assays identifying RSV epitopes included mice (307), cows (88), rabbits (39), guinea pigs (2), rhesus monkeys (2) and Cynomolgus monkeys (1).

Epitopes have been reported for all ten RSV protein antigens: fusion (F) glycoprotein, attachment (G) glycoprotein, RNA-dependent RNA polymerase (L), nucleoprotein (NP), matrix (M), matrix 2 (M2), non-structural protein 1 (NS1), non-structural protein 2 (NS2), phosphoprotein (P) and the small hydrophobic protein (SH). However, the degree of coverage varied greatly among individual antigens. Not surprisingly, the major surface glycoproteins, F and G, represented the majority of identified epitopes (37% and 35%, respectively), followed by L (12%), NP (5%), M2 (4%), M (3%), NS2 (2%), P (1%), SH (1%) and NS1 (1%). Fig 1 shows the distribution of epitopes for each RSV antigen and further illustrates the relative proportion of response types (antibody/B cell, T cell or MHC ligand binding/elution) for each antigen. At the level of antibody responses, epitopes from F and G clearly predominated. The other antigens had far fewer total reported epitopes, and they were primarily associated with T cell responses and/or MHC binding.

Functional analysis of the humoral response to the predominant surface antigens F and G

The predominance of epitopes derived from F and G was not unexpected, as these antigens are well-documented as the major targets of immune response to RSV infection [22]. In particular, F has received significant attention in the characterization of RSV immunity [e.g. Motavizumab (Numax), palivizumab (Synagis), RSV SAM (self-amplifying message) vaccine, RSV-IGIV (RespiGam), [35] due to its ability to induce neutralizing antibodies and to play a putative role in protection from RSV.

To characterize in depth the B cell/antibody data for the F and G proteins, we focused on the subset of data describing functional assays, including only data related to *in vivo* protection.
assays and those defining in vitro correlates of protection, virus neutralization/fusion-inhibition (described in the Methods). From here forward, we will refer to this specific subset of data as ‘functional epitopes.’ Many epitope mapping studies are carried out by testing overlapping 15-20-mer peptides spanning the entire length of an antigen. While this is a standard approach for epitope mapping, the interaction it defines is less frequently indicative of a biologically relevant activity. Assays that defined binding alone have therefore been excluded.

Tables 1 and 2 provide a summary of all linear and discontinuous B cell epitopes associated with virus neutralization and/or in vivo protection, respectively. Data for linear epitopes include epitopes identified in assays using both polyclonal sera (PC) and monoclonal antibodies (mAbs). Discontinuous epitopes were defined for both human and murine mAbs, and include well-known mAb D25 [35], palivizumab (humanized murine mAb derived from mAb 1129), and motavizumab (a second-generation humanized mAb derived from palivizumab) [36–38]. Some of the epitopes were identified via protection following passive transfer of epitope-specific antibodies or survival frequency (number protected/number tested), and some were associated with cross-protection (response to other strains or to BRSV). It is important to note that some epitopes, which were originally described as linear, were subsequently further refined for specificity as discontinuous epitopes (e.g., motavizumab epitope). It is also of note that only three of these mAbs were defined in human hosts (D25, Fab19 and MPE8), while the remainder were derived from murine hosts.

For the F protein, there are a total of 35 mAbs reported to date, representing 22 unique functional epitopes (unique site/Ab), the majority of which are discontinuous and often overlapping, clustering around specific regions (discussed further below). The IEDB defines an epitope as any unique molecular structure shown to interact with an antibody (see Methods). However, we acknowledge that overlapping binding sites can be considered as either separate epitopes or grouped together in some cases as part of a larger antigenic region, and this will be noted wherever possible going forward. For the G protein, far fewer discontinuous epitopes
have been reported (7), and linear functional epitopes cluster very closely around the region containing residues ~140–200. All discontinuous G epitopes are also contained within this region.

Table 2. Discontinuous B cell epitopes associated with virus neutralization or in vivo protection.

| Epitope        | Source   | Antibody | Assay | Assay Antigen | PMID        |
|----------------|----------|----------|-------|---------------|-------------|
| Q142, K145     | G HRSV A | 021/5G (IgG1) | VN    | HRSV A Mon/3/88 | 9349460     |
| F163, F165     | G HRSV A | 021/1G (IgG2a) | VN    | HRSV A Mon/3/88 | 9349460     |
| T181           | G HRSV A | 021/19G (IgG1) | VN    | HRSV A Mon/3/88 | 9349460     |
| R188           | G HRSV A | 021/18G,021/2G, 021/17G, 021/20G, 021/22G | VN    | HRSV A Mon/3/88 | 9349460     |
| R188, K192     | G HRSV Long | PC | Prot, VN | HRSV Long | 12744884 |
| R244           | G HRSV A | 021/9G, 021/4G, 021/16G (IgM) | VN    | HRSV A Mon/3/88 | 9349460     |
| T282, L286     | G HRSV A | 021/7G (IgG1) | VN    | HRSV A Mon/3/88 | 9349460     |
| F32, K272      | F HRSV A2 | 1142 | VN    | HRSV A2 | 9878616     |
| T50, L305, G307, I309, D310 | F HRSV A2 | MPEB* | VN, Prot | HRSV A2, Long, HRSV B, HMV, PVM, BRSV (RB94)* | 23955151 |
| N63, K65, E66, K68, K196, N197, Y198, I199, D200, K201, Q202, L203, L204, P205, I206, V207, N208, K209, Q210 | F HRSV A2 | D25 (IgG1)* | VN    | HRSV A2 | 23618766 |
| S190, L258, K272 | F HRSV Long | 7C2 | VN    | HRSV Long, A2* | 1383404     |
| N216, N262, N268, K272 | F HRSV Long | 47F, AK13A2 | VN    | HRSV Long, A2* | 1383404     |
| A241, K421     | F HRSV A2 | 1308F, 1302A | VN    | HRSV A2 | 9878616     |
| L258, S259, N262, D263, M264, P265, I266, T267, N268, D269, K271, K272, S275 | F HRSV | 17HD9** | VN    | HRSV B | 24499818 |
| N262           | F HRSV A2 | 1153 | VN    | HRSV A2 | 9878616     |
| N262, N268     | F HRSV Long | 47F | VN    | HRSV Long | 1688629     |
| I266           | F HRSV A2 | Fab 19 (IgG1)* | VN    | HRSV A2 | 9878616     |
| N268           | F HRSV Long | 11 | VN    | HRSV Long, A2* | 1383404     |
| S275           | F HRSV A2 | 1129 | VN    | HRSV A2 | 9878616     |
| K272, S275     | F HRSV A2 | Palivizumab | VN    | HRSV | 17623075    |
| S255, L258, S259, N262, N268, D269, K271, K272, S275, N276 | F HRSV | Motavizumab | VN    | HRSV | 21549714    |
| K272           | F HRSV A2 | 151, 1200 | VN    | HRSV A2 | 9878616     |
| N276           | F HRSV A2 | 1237, 1214 | VN    | HRSV A2 | 9878616     |
| P389           | F HRSV A2 | 1269, 131-2a, 55F | VN    | HRSV A2 | 9878616     |
| R429           | F HRSV Long, A2 | 19, 20, 56F, 57F, RSV19 | VN    | HRSV Long, A2 | 9878616, 1383404 |
| K272           | F BRSV strain 127 | B4*** | VN    | HRSV Long, A2 | 1383404     |
| I432, K433, V447 | HRSV B | 7.936 | VN    | HRSV Long, A2 | 9658147     |
| S436           | HRSV B | 9.432 | VN    | HRSV Long, A2 | 9658147     |
| P389           | HRSV Long | 55F | VN    | HRSV Long, A2 | 9658147     |

VN, virus neutralizing; Prot, in vivo protection; bold font indicates also cited by Swanson et al PNAS 2011

*human

**, rhesus

***bovine; Residues 262 and 272 also critical in seropositive humans [PMID:24499818]. In vivo protection for human mAbs represents those used in passive transfer experiments wherein the human-derived mAb is shown to protected recipients (most often rodents) from lethal challenge.

doi:10.1371/journal.pone.0127108.002
Structural analysis of the fusion protein epitopes

Previous work suggested that the majority of neutralizing epitopes may be elicited by the pre-fusion conformation of F [19, 26]; however, several neutralizing epitopes also recognize the post-fusion protein [19, 39–42]. Therefore, we investigated the overall repertoire of reported functional epitopes by mapping them onto the F protein’s pre-fusion and post-fusion three-dimensional (3D) structures. We were interested in evaluating the overall accessibility of the functional epitope sites and examining if these differed in pre- and post-F structures.

Using the IEDB’s Homology Mapping tool, epitope sites were mapped to the protein structures from the Protein Data Bank (PDB) of the pre-F [PDB: 4HJW] and post-F (Fig 2) [PDB: 3RKI] conformations. Functional epitopes are shown in yellow. Applying the structural blueprint provided by Colman and Lawrence defining the head, neck and stalk regions of F [43; defined on post-F structure], we were able to determine that of all 115 residues considered in this mapped functional antibody epitope subset, 21 were located in the head region (aa33-55 and 291–435), 59 in the neck region (aa56-105, 221–290 and 436–454) and 35 in the stalk (aa171-220). Here, the majority of epitope sites reported to date cluster to neck and stalk regions, with fewer sites located on the head or apex of the protein. In comparing the two states of the protein, it appears that in the post-F conformation in which the neck and stalk structure is formed, the solvent accessibility of some of these sites was decreased (Fig 2) [The lack of available PDB structures prevented a similar analysis for the G protein].

Thus to quantify and compare the change in accessibility from pre- to post-F, we calculated residues relative solvent accessibility (RSA) for each structure. Fig 3 shows RSA data for all...

Fig 2. Functional B cell epitopes mapped to F protein. Functional epitopes, comprising 115 total residues, are mapped to the RSV F protein (epitopes are shown in yellow). Three dimensional structures 4JHW (pre-fusion) and 3RKI (post-fusion) were selected to visualize the location of all residues using the IEDB Homology Mapping Tool. This considers all functional (neutralizing and/or protective) linear and conformational epitopes described to date in the literature.

doi:10.1371/journal.pone.0127108.g002
Figure 3. a.) Epitope residues with predicted RSA values that support pre- or post-F binding (unchanged pre v. post)

MOTA | PALI | Ch101F | 1153 | 11 | 151, 1200, 84 | 1279 | 1273, 1214 | 1269, 131-2a, 55F | 19, 20, 56F, 57F | 9, 432
---|---|---|---|---|---|---|---|---|---|---
S255 | L258 | S259 | N262 | N268 | D269 | K271 | S275 | N276 |
| K272 | T423 | N262 | N268 | K272 | S275 | N276 | P389 | R429 | S436 |

b.) Epitope residues with predicted RSA values that support pre-F binding preference

| 17HD9 | D25 | MPE8 | AK13A2, 47F | Fab19 | 1308F, 1302A | 3 |
---|---|---|---|---|---|---|
L253 | L258 | N63 | N63 | T50 | T50 | N216 | A173 | A173 |
S259 | S259 | K65 | K65 | L305 | L305 | N216 | K174 | K174 |
N262 | N262 | E66 | E66 | G307 | G307 | N216 | K174 | K174 |
D263 | D263 | K68 | K68 | I309 | I309 | A177 | N175 | N175 |
M264 | M264 | K196 | K196 | A210 | A210 | A177 | V178 | V178 |
P265 | P265 | N197 | N197 | A241 | A177 | V178 | V178 |
I266 | I266 | Y198 | Y198 | A173 | A173 |
T267 | T267 | J199 | J199 | I266 | I266 | K174 | K174 |
N268 | N268 | D200 | D200 | I266 | I266 | K174 | K174 |
D269 | D269 | K201 | K201 | I266 | I266 | K174 | K174 |
K271 | K271 | Q202 | Q202 | I266 | I266 | K174 | K174 |
K272 | K272 | L203 | L203 | I266 | I266 | K174 | K174 |
S275 | S275 | L204 | L204 | I266 | I266 | K174 | K174 |

| Site II, Pre/Post | Site II, Pre/Post | Pre | Site II | Site II |
---|---|---|---|---|
I266 | I266 | Y198 | Y198 |
T267 | T267 | J199 | J199 |
N268 | N268 | D200 | D200 |
D269 | D269 | K201 | K201 |
K271 | K271 | Q202 | Q202 |
K272 | K272 | L203 | L203 |
S275 | S275 | L204 | L204 |

| Site IV, Pre/Post | Site IV |
---|---|
I266 | I266 |
T267 | T267 |
N268 | N268 |
D269 | D269 |
K271 | K271 |
K272 | K272 |
S275 | S275 |

C.) Epitope residues with predicted RSA values that support post-F binding preference
monoclonal antibody epitope residues. In the figure, red denotes RSA of >40% (exposed), blue denotes 0–7% (buried) and no color 7–40% (intermediate-exposure), and for those residues with RSA values that differ on each conformation the results are displayed side-by-side for pre- versus post-F. Further, for each epitope we indicate where the mAb was reported to bind (either pre- or post-F if known), as well as the antigenic site (if known). Of the 22 unique functional epitopes considered, 11 showed no change in the residues RSA values from pre- to post-F (Fig 3A). These include, mAbs, mota, pali, Ch101F, 1153, 11, 1200, B4, 1129, 1237, 1214, 1269, 131-2a, 55F, 19, 20, 56F, 57F, and 9.432. Another 11 show distinct patterns between pre- and post-F. Sites for mAbs 17HD9, D25, MPE8, AK13A2, 47F, Fab19, 1308F, 1302A and 3 show higher RSA values for pre-F (Fig 3B), while sites for mAbs 101F, 1142, 7C2 and 7.936 show higher RSA values for post-F (Fig 3C). These results may be of interest, for while the binding preference to pre-F has been established for mAbs D25 and MPE8, it is as yet undetermined for AK13A2, 47F, Fab19, 1308F, 1302A and 3. Similarly, the calculated RSA values suggest a binding preference for mAbs 1142, 7C2, and 7.936 to post-F. Thus we found correspondence in the RSA values for those mAbs previously shown to bind preferentially to a particular conformation and present RSA values suggestive of a binding preference for 14 functional mAbs that have yet to be differentiated. While it is not within the scope of the present analysis, the data presented here support future testing of this latter group of mAbs. Thus the RSA values of 15 of the 22 sites were either unchanged (no difference between pre and post) or were suggestive of a binding preference to F in its post-fusion conformation suggesting that epitopes to post-F are biologically relevant.

Combined analysis of RSA values, sequence conservation and prediction outcomes for functional epitopes on F

The ability to map or identify B cell epitopes has been historically difficult, due in large part to the conformation-dependent nature of these determinants, which imposes numerous technical challenges related to the analysis of proteins in their native, 3-dimensional state. Also likely at issue, is the more practical problem of limited access to samples from human donors. Consequently, there has been increased interest in supplementing the current experimental methods with other analyses and bioinformatics tools. The idea being that these additional analytic tools may help decrease time and effort by identifying specific regions or sites of the greatest potential for activity that could then be tested empirically in the lab.

Using the tools at our disposal, we next sought to explore the relationship (if any) between solvent exposure (RSA values), evolutionary conservation scores and epitope prediction outcomes to determine if these measurements, when used in combination, could be discriminating factors in identifying true epitopes. Because the IEDB captures both positive and negative data, residues shown to be uniquely negative (non-binding) can be used to analyze truly non-immunogenic residues or regions. Here, RSA values and evolutionary conservation scores were calculated for non-binding, negative residues and compared to those calculated for all positive
epitopes considered thus far from the subset of 22 mAbs (from Fig 3). This was done separately for each PDB structure available for pre-F (4JHW and 4MMS) and post-F (3RKI and 3RRR).

We found that on the pre-F PDB structures, residues from all positive residues (known epitopes) had a tendency to be solvent exposed in comparison to those from non-binding, negative residues, given the average RSA values of 43% and 12%, respectively (similar values were obtained for the PDB pre-F structures 4JHW and 4MMS). By contrast, on post-F PDB structures there was no difference observed in RSA values between positive residues (epitopes) and negative residues, with the average values for positive epitopes of 29% and 27% (again, similar result were observed for post-F PDBs 3RKI and 3RRR). Thus while positive and negative residues are discriminated on the pre-F structure by calculated RSA values, on post-F, both positive and negative residues are equally solvent accessible, showing RSA values indicating intermediate or partial exposure.

Next, we calculated residue conservancy scores for each PDB F structure and again made comparisons between known epitopes (positives) and negative residues. Here we found no significant difference between residue conservancy scores for positive and negative residues.

Lastly, we compared epitope prediction outcomes between the pre- and post-F conformations using two published B cell prediction methods, ElliPro [29] and Discotope (available on IEDB) [30, 31]. The predicted epitope scores calculated by these methods correlated well among pre-F conformations ($r^2 = 0.52$ for [PDB: 4JHW]; $r^2 = 0.49$ for [PDB: 4MMS]), but do not for post-F conformations. When we compared prediction outcomes for each method against known positive and negative residues we found that while there was no statistical significance, there was a correspondence with the observed scores, such that epitope prediction scores for known positive residues were consistently higher than that of negative residues. For example, the average ElliPro scores for positive residues were 0.63, 0.65, and 0.51 for PDBs 4JHW (pre), 4MMS (pre), and 3RKI (post), respectively, whereas the average scores for negative residues were 0.37, 0.37 and 0.28, respectively. Since both of these prediction methods (algorithms) take into account residue solvent accessibility, as well as overall protein structure, it is likely that the more globular pre-F conformation may be considered more suitable for these specific methods than the elongated post-F conformation.

Thus the results of the combined analysis reveal a correspondence of RSA values and epitope prediction scores with positive and negative residues, but this was the case only when considering the pre-F structures. There was no observed tendency for the residues in functional epitopes to be more or less conserved than in reported non-binding, negative residues. No significant correlation was found between epitope prediction scores, RSA values and sequence conservation considered together for any structure (data not shown). All results for each of the analyzed structures are summarized in the S1 Table, which provides for each residue the conservancy score, RSA values, ElliPro and Discotope prediction scores.

**T cell epitope reactivity**

Both CD4⁺ and CD8⁺ T cell subsets have been shown to play a critical role in protection from disease, and while involvement for each subset in disease enhancement has been implicated in certain animal models, in humans a balanced CD4⁺ Th1:Th2 cytokine response seems to promote development of neutralizing antibodies, while CD8⁺ cytolytic activity effects viral clearance from the lungs [44, 45]. Here we cataloged all human epitopes associated with *in vitro* IFNγ production (CD4/CD8), degranulation (perforin/granzyme B release), cytolytic activity (CTL), and *in vivo* protection. Unlike the case described for B cell/Ab epitopes above, we were not as limited in repertoire and could therefore select the human-specific subset of T cell data.
More than 50 peptides, from F, G, M2, M, NP and NS1, have been reported in the context of IFNγ (CD4+ and CD8+) and/or cytotoxicity (CD8+ T cell) [Tables 3–5]. NP represents the greatest source of CD8+ epitopes associated with IFNγ production and cytotoxicity, whereas epitopes associated with CD4+ IFNγ were most often reported from F. These data highlight the potential utility of NP as a vaccine antigen, and also show that in addition to being a major target of protective antibody responses, F is also a target of CD4+ and CD8+ T cell responses. Interestingly and perhaps not surprisingly, many of the epitopes described for CD8+ T cells are derived from antigens active within the cytoplasm (e.g. RNA binding role) [Tables 3 and 4], whereas many of the CD4+ T cell epitopes are derived from extracellular antigens active at the cell surface [Table 5].

As a further analysis, a broad query was performed to identify all overlapping T and B cell epitopes that were recognized by children/infants and adults following (post) or during (acute) natural RSV infection (Table 6). These are indicated in Table 6 by asterisks. The table also includes the antigen name, epitope position, response frequency (number of respondents/number tested), the calculated RFscore (see Methods) and the function/location of the derivative antigen (if known) in viral pathogenesis. Here, ‘overlapping epitopes’ represent those residues that are recognized by both antibodies and T cells. In several instances we found that the exact same peptide could induce antibody and T cell response.

Finally, we were interested in reported tetramer data, which are useful tools for studying T cell responses in the research and vaccine evaluation settings. A total of 11 RSV-derived tetramers were described, including epitopes restricted by both HLA class I and class II alleles (Table 7). All but one of these structures were also associated with a functional response (CTL, cytokine production, in vivo survival), making these potential reagents for use in evaluating candidate vaccine formulations for specific T cell response types.

**Discussion**

Herein we have provided an analysis of RSV specific immune epitope data with the goal of examining this body of work for its application to vaccine design and development. To this end, we first provided an overview of all available data, showing overall coverage and identifying critical knowledge gaps. Then we further analyzed the cumulative RSV epitope data from the standpoint of functional responses, and used a combinational approach to characterize antigenic structure and epitope location. This work represents a comprehensive analysis of RSV epitope data that provides an update for previous work by Anderson et al. [46].
Our initial assessment of the cumulative data revealed that the vast majority of epitope mapping has focused on just two antigens, F and G. While this is not surprising, it may be useful to pursue the expanded epitope mapping of this virus, not only to complete our understanding of these two critical proteins, but perhaps to also include additional antigens to more fully understand the immune response to all pertinent antigens having key roles in viral pathogenesis. Further, the balance of T cell versus antibody epitopes should be addressed, especially in light of increasing evidence from the literature regarding known correlates of protection, which suggests a role for both humoral and cellular responses in disease resolution. If it is found that combined antibody and T cell responses prove to be efficacious and safe, antigens such as NP might provide a potential target for inducing CMI, allowing the vaccine to generate the needed balance of both humoral and cellular responses. Indeed, our review of the T cell epitope data suggested there may be a need to incorporate multiple antigens (besides F) into candidate vaccines in order to optimize required response, but further empirical testing is warranted to make this determination.

Somewhat unexpected was the low number of human data; only 32% of the epitopes described to date are derived from human hosts, and of these a mere 3 epitopes were defined in humans describing neutralizing or protective activity. Thus our assessment of the totality of RSV epitope data is 1) that additional mapping of all proteins is warranted, including F and G, 2) a greater breadth in T cell, as well as B cell/antibody epitope repertories is needed, especially in humans and specifically using functional assays (neutralization, cytolysis, in vivo protection, etc.) and 3) future epitope discovery or mapping in the context of human disease, especially infants and young children would be beneficial to increase the characterization of immunity at

---

Table 4. Epitopes that induce IFN$\gamma$ production from human CD8+ T cells.

| PMID    | Epitope         | Position | Protein | Role/Site     | Virus | MHC Allele |
|---------|-----------------|----------|---------|---------------|-------|------------|
| 15269378 | AELDRTEEY       | 64–72    | M       | VA/CP         | HRSV  | HLA-B44    |
| 15269378 | RLPAVLKK        | 151–159  | M       | VA/CP         | HRSV  | HLA-A3     |
| 15269378 | IPYSGLLVV       | 195–203  | M       | VA/CP         | HRSV  | HLA-B51    |
| 15269378 | YLEKESIYY       | 229–237  | M       | VA/CP         | HRSV  | HLA-A1     |
| 15755607 | FVPCSICSNPTCAICKRIP | 170–190 | G       | HBD           | HRSV A2 | HLA-Class I |
| 15269378 | LAKAVIHTI       | 41–49    | NS1     | Inh IFN/CP    | HRSV  | HLA-B51    |
| 11024156 | RARRELPRF*      | 106–114  | F2      | EC            | HRSV A2 | HLA-B57    |
| 12667209 | RELPRFMNYT      | 109–118  | F2      | EC            | HRSV  | HLA-A1     |
| 11024156 | IAVGILLYCKA*   | 542–552  | F1      | TM/CP         | HRSV A2 | HLA-Cw12   |
| 17931110 | QLLSSSKYT       | 16–24    | NP      | RB/CP         | HRSV Long | HLA-A*02:01 |
| 12805430 | KLCGMLITEDANH  | 46–59    | NP      | RB/CP         | HRSV A2 | HLA-Class I |
| 17931110 | KMLKEMGEV      | 137–145  | NP      | RB/CP         | HRSV Long | HLA-A*02:01 |
| 12805430 | STRGSSRVEGIFAG | 232–245  | NP      | RB/CP         | HRSV A2 | HLA-Class I |
| 12805430 | AYGAGQVMLRWGLV | 250–263  | NP      | RB/CP         | HRSV A2 | HLA-Class I |
| 12805430 | AGQVMLRWGLAKS  | 253–266  | NP      | RB/CP         | HRSV A2 | HLA-Class I |
| 12805430 | VMLRWGLAKSVKN  | 256–269  | NP      | RB/CP         | HRSV A2 | HLA-Class I |
| 12805430 | AGFYHILNNPKASL | 298–311  | NP      | RB/CP         | HRSV A2 | HLA-Class I |
| 17931110 | ILNPKASL       | 303–311  | NP      | RB/CP         | HRSV Long | HLA-A*02:01 |
| 12667209 | NPKASLLSL      | 306–314  | NP      | RB/CP         | HRSV  | HLA-B7     |

Role/Site abbreviations are included to indicate the role of the protein antigen in viral pathogenesis. VA: viral assembly; CP: cytoplasm; TM: transmembrane; EC: extracellular; HBD: heparin binding domain 184–198; RB: RNA binding; Inh IFN; inhibits IFN-mediated antiviral response; SS: signal sequence/N-terminus.

doi:10.1371/journal.pone.0127108.t004
the molecular level. Historically speaking, epitopes have not played a prominent role in RSV vaccine development; however, going forward, this information may help to more fully elucidate certain as yet poorly understood or partially characterized aspects of RSV immunobiology. While animal models of RSV have historically provided essential platforms through which we have gained valuable insights with respect to vaccine-enhanced disease and virus-induce airway hypersensitivity, and in which to test proof-of-principle for prophylactic and therapeutic agents [47], none truly recapitulate natural disease and therefore a better understanding of the human epitope repertoire will likely help hasten vaccine development.

As previously mentioned, the second part of our analysis builds on previous insights from McLellan et al. [18–20], and others, with regard to relationship of antigen conformation to

## Table 5. Epitopes that induce IFNγ production in human CD4+ T cells.

| PMID     | Epitope                | Position | Protein | Role/Site | MHC Allele                        |
|----------|------------------------|----------|---------|-----------|-----------------------------------|
| 12502814 | KANAITTILTAVTFCFAS     | 7–24     | F       | SS        | HLA-DRB1*01:01; DRB1*04:01       |
| 12502814 | TILTVTFCFASGQNIIE      | 13–30    | F       | SS        | HLA-DRB1*01:01                   |
| 12502814 | GONITFEOYCSTSAVS      | 25–42    | F       | EC        | HLA-DRB1*04:01; DRB1*07:01       |
| 12502814 | EFYQSTCSAVKGYLSAL     | 31–48    | F       | EC        | HLA-DRB1*07:01; DRB1*04:01       |
| 12502814 | GYLSRTGWYTSVIITE      | 43–60    | F       | EC        | HLA-DQ5; HLA-DRB1*16:01          |
| 12502814 | RTGWYTSVIETLNSKIE     | 49–66    | F       | EC        | HLA-DRB1*04:07                   |
| 12502814 | SVITIENKINCNIGT       | 55–72    | F       | EC        | HLA-DRB1*07:01                   |
| 12502814 | DAKVLKLQELDKYKNAV     | 73–90    | F       | EC        | Class II-allele undetermined      |
| 12502814 | IOKELDKYKNAVTELOLL    | 79–96    | F       | EC        | HLA-DRB1*04:01                   |
| 12502814 | KYKNATTELQMLMQSTPP    | 85–102   | F       | EC        | HLA-DRB1*04:01                   |
| 12502814 | RELPRFNYLTNNAKTN      | 109–126  | F       | EC        | Class II-allele undetermined      |
| 12502814 | MNYTLNNNKAATNVTLSKK   | 115–132  | F       | EC        | Class II-allele undetermined      |
| 12502814 | NKAUVSSLNSGVSVLTSKV   | 175–192  | F       | EC        | HLA-DRB1*07:01                   |
| 12502814 | LDLKYNIDKQLPIVNQ      | 193–210  | F       | EC        | HLA-DRB1*11:01                   |
| 12502814 | RLEITREFSNAVYTP       | 229–246  | F       | EC        | HLA-DRB1*11:01                   |
| 12502814 | REFSNAGVTPVSTYML      | 235–252  | F       | EC        | HLA-DRB1*01:01                   |
| 12502814 | PITNDQKKLMSNNVQIYR    | 265–282  | F       | EC        | HLA-DR3; DQ; DQ2                 |
| 12502814 | KKLMSNNVQIYRQOQSYISI | 271–298  | F       | EC        | HLA-DQ; DR3; DQ2                 |
| 12502814 | ELYAVYQVLPLYGVIDTP    | 295–312  | F       | EC        | HLA-DQ5; HLA-DQ6                 |
| 12502814 | VQLPLYGIDTPCWLHT     | 301–318  | F       | EC        | HLA-DR; DQ                       |
| 12502814 | TDRGWYCDNASVFSPQQ    | 337–354  | F       | EC        | HLA-DRB1*11:01; DRB1*13:01; DR3; DQ6 |
| 12502814 | YDCKIMTSTKTVSSSVIT   | 391–408  | F       | EC        | HLA-DRB1*04:01                   |
| 12502814 | SLGAIVSCYGTKTCTASN   | 409–426  | F       | EC        | HLA-DRB1*15:01; DRB5*01; DRB1*07:01 |
| 12502814 | KNRGIIKTFSNGCDYVSNI  | 427–444  | F       | EC        | HLA-DRB1*04:01                   |
| 12502814 | YYYVKQEGKSLVYKQEGPI | 457–474  | F       | EC        | HLA-DRB1*01:01                   |
| 12502814 | VKGEPINFYDPLVFPSD   | 469–486  | F       | EC        | HLA-DRB1*15:01; DRB5*01          |
| 12502814 | NAGKSTTNIMTTIIIIVI  | 517–534  | F       | EC/TM     | HLA-DQB1*0502; DPB1*16:01       |
| 12502814 | LIAVGLULLLYCARSTPVT | 541–558  | F       | TM/CP     | HLA-DRB1*07:01                   |
| 14747542 | FHFEVFNVFV          | 163–171  | G       | HBD       | HLA-DBP1*04:02; DBP1*04:01       |
| 14747542 | HFEVFNVFVPC       | 164–173  | G       | HBD       | HLA-DBP1*04:01; DBP1*04:02; DBP1*02:01; DBP1*02012 |
| 15756607 | VFPCISCNPTCWACKRIP | 170–190  | G       | HBD       | Class II-allele undetermined      |
| 14747542 | RFIAKPMME        | 248–255  | M       | VA/CP     | HLA-DRB1*16:01                   |

Role/Site abbreviations are included to indicate the role of the protein antigen in viral pathogenesis. VA: viral assembly; CP: cytoplasm; TM: transmembrane; EC: extracellular; HBD: heparin binding domain 184–198; RB: RNA binding; Inh IFN: inhibits IFN-mediated antiviral response; SS: signal sequence/N-terminus.

doi:10.1371/journal.pone.0127108.t005
Table 6. ImmunomeBrowser analysis of B and T cell epitopes.

| Epitope ID | Sequence | Cell | Ag/Position | R/T | RFscore | Function |
|------------|----------|------|-------------|-----|---------|----------|
| 64978      | TLNKDQLLSSSKYTQQRSTG** | B    | NP(11–30)  | 2/2 | 0.29 (0.71) | N-arm/CP |
| 51436      | QLLSSSKYT | T    | NP(16–24)  | 2/10| 0.06 (0.14)  | N-arm/CP |
| 61410      | SSTRGSRVEGIFAGLFMNA** | B    | NP(231–250)| 2/2 | 0.29 (0.71) | NTD/CP   |
| 61861      | STRGSRVEGIFAG***  | T    | NP(232–245)| 7/37| 0.12 (0.07) | NTD/CP   |
| 48008      | PIVNKQCSISNIETVIEFQQ | B    | F(205–225) | 2/2 | 0.42 (0.58) | EC;HRA   |
| 59844      | SNIETVIEFQOKNRLEITREFSVNAGVTTPVSTYMLTNSSELLSLINDMPITNDQKKLMS** | B    | F(215–275) | 5/9 | 0.31 (0.25) | EC;DI    |
| 44221      | NIETVIEFQOKNRLELEITRE | B    | F(216–232) | 2/2 | 0.29 (0.71) | EC;DI    |
| 25806      | IEFOQKNNRLLEITRE  | B    | F(221–236) | 2/2 | 0.29 (0.71) | EC;DI    |
| 53499      | REFSVNAGVTTPVSTYMLTNSSELLSLINDMPITNDQKKLMS**  | B    | F(235–275) | 5/9 | 0.31 (0.25) | EC       |
| 139186     | NSELLSLINDMPITNDQKKLMSNN | B    | F(254–277) | 4/4 | 0.50 (0.50) | EC       |
| 57525      | SELLSLINDMPITNDQKKLMSNNV | B    | F(255–278) | 4/4 | 0.50 (0.50) | EC       |
| 57524      | SELLSLINDMPITNDQKKLMS**   | B    | F(255–275) | 4/10| 0.20 (0.20) | EC       |
| 57525      | SELLSLINDMPITNDQKKLMSNNV | T    | F(255–278) | 2/2 | 0.29 (0.71) | EC       |
| 17402      | FPSDEF**     | B    | F(483–488) | 2/2 | 0.29 (0.71) | EC;HRB   |
| 46727      | NYYDPLVFPSDEFDAS*    | T    | F(476–491) | 2/2 | 0.29 (0.71) | EC;HRB   |
| 125242     | RQNKPPSKPNNDFHFEVFNFVFP**** | B    | G(151–172) | 22/51| 0.34 (0.09) | Cys-noose|
| 51730      | QNKPPSKPNDHFHE   | T    | G(152–166) | 2/2 | 0.29 (0.71) | Cys-noose|
| 18255      | FVPCISCNPTCWAICKRIP | B    | G(170–190) | 6/6 | 0.59 (0.41) | Cys-noose|
| 18255      | FVPCISCNPTCWAICKRIP | T    | G(170–190) | 4/5 | 0.40 (0.40) | Cys-noose|
| 94738      | WAICKRIPNKKP   | B    | G(183–194) | 2/2 | 0.29 (0.71) | HBD      |
| 100637     | WAICKRIPNKKPG  | T    | G(183–195) | 4/4 | 0.50 (0.50) | HBD      |
| 94429      | AICKRIPNKKPG   | B    | G(184–195) | 2/2 | 0.29 (0.71) | HBD      |
| 1862       | AICKRIPNKKPGKKT | T    | G(184–198) | 2/2 | 0.29 (0.71) | HBD      |

R/T, number responded over number tested; RFscore, response frequency score; N-arm, N-terminal arm; NTD, N-terminal domain; CP, cytoplasmic; EC, extracellular; HBD, heparin binding domain; HRA/HRB, heptad repeats; DI, docking inhibition; Cys-noose, cysteine noose; bovine host*, natural infection in children/infants**, natural infection in adults***; bold indicates overlap.

doi:10.1371/journal.pone.0127108.006
epitope accessibility, and in particular in this report, epitopes known to be associated with protective responses. Extensive modeling by McLellan et al of the F protein using monoclonal antibodies revealed two important insights: 1) that there is structural preservation of important neutralizing epitopes in the post-fusion state, suggesting that this conformation would elicit neutralizing antibody responses and was therefore a useful target as vaccine antigen, and 2) that critical sites on pre-F are also protective. The work of McLellan et al. clearly attributes the greatest contribution to neutralizing response to the pre-fusion state of the F protein. Our review and analysis of the cumulative data (all reported to date) for ‘functional’ (neutralizing/protective) epitopes against F suggests that a majority of identified sites available for binding in the pre-F conformation are also accessible in the post-F conformation.

The current epitope data are as yet incomplete to determine the extent of neutralizing sites exclusive to either state because a comprehensive mapping of all potential neutralizing sites has not been performed. Thus, it is possible that in the course of natural infection sites do exist on both pre- and post-F and do contribute to disease resolution. Indeed, it is possible that the epitope residues located within the 'head and stalk' regions of F function to prevent neutralizing on the pre-fusion conformation, whereas those epitopes found on the 'apex or head' function directly to inhibit contact with the host cell. However, no final conclusion can be drawn until further work comparing responses to both pre- and post-F states in humans is undertaken.

Going forward, it may be important to establish to what extent epitopes on each state contribute to RSV disease resolution in humans, especially the target population, children 6 months to 2 years of age, as these data are yet unavailable in the current literature. In fact as noted above, very little epitope analysis of humans during and following infection disease has been published, especially neutralizing sites specific to this host (infants and adults). This is surprising given the ubiquitous nature of this pathogen, by comparison to influenza A virus as an example. To date, there are 379 assays defining more than 50 flu A neutralizing sites in humans captured from the peer-reviewed literature in the IEDB. Historically, we do know that vaccine-induced partial immunity against RSV has been a double-edge sword. If we can more fully characterize the nature of protection at the molecular level against RSV we may, for

Table 7. List of validated tetramers (epitope/allele combinations).

| Tetramer       | Antigen       | Allele       | Functional Response | PMID          |
|----------------|---------------|--------------|---------------------|---------------|
| HNYFEWPHALLVQR | M2 (25–39)    | H-2-IAb IFNy| 19264776, 24510524  |
| NYFEWPHALLVQR  | M2 (26–39)    | H-2-IAb NR  | 20686045            |
| SYIGSINNI*     | M2 (82–90)    | H-2-Kd CTL, Prot, IFNy | 19 references  |
| YIGSINNI       | M2 (83–90)    | H-2-Kd IFNy | 18816384            |
| NAITNAKII*     | M (187–195)   | H-2-Db CTL, IFNy | 17275872, 19153229, 20833834, 20686045, 21118816, 22144888 |
| VYNTVISYI*     | M2 (127–135)  | H-2-Kd CTL, IFNy | 17182672, 18662734  |
| NKGAFKYPQSQFI  | M (209–223)   | H-2-IAb IFNy, IL-2, Prot | 19264776, 20686045, 24510524 |
| YLEKESIYY*     | M (229–237)   | HLA-A1 IFNy | 15269378, 15838799, 16301748 |
| NPKASSSL*      | NP (306–314)  | HLA-B7 CTL, IFNy | 15269378, 15838799, 10906229 |
| KYKNAVTEL*     | F (85–93)     | H-2-Kd CTL, Prot, IFNy | 11591747, 23015695, 24572813 |
| CYLTDRAI*      | P (261–269)   | H-2-Kd IFNy, Prot | 16272314, 22940382  |

*Naturally eluted peptide; Prot, in vivo protection or survival; IFNy, ELISPOT or ELISA; CTL, cytotoxicity assay; NR, None reported to date.

doi:10.1371/journal.pone.0127108.t007
example, be better positioned to answer the question, ‘are the majority of the neutralizing epitopes present on pre-F, or are these critical epitopes located on both pre- and post-F?’ The answer may influence the chosen vaccine modality (recombinant vector expressing whole antigen, plasmid DNA, live-attenuated, purified protein with adjuvant, etc.) and its complexity from a formulation standpoint.

As part of our investigation into the nature of protective epitopes, we sought to determine to what extent, if any, functional antibody and T cell epitopes residues overlapped. We reasoned that such analysis was relevant to vaccine design and development since evidence to date demonstrates that the generation of a combined humoral and cellular response is optimal against RSV. Thus considering the antibody data together with the T cell data may be of value for vaccine development, especially if the aim is to develop, for example, a subunit vaccine (say, 1–2 antigens) that targets both humoral and cellular immunity. Interestingly, we found that there was overlap between certain Ab and T cell sites (CTL/IFNγ epitopes with neutralizing linear and discontinuous epitopes). Moreover, some of these overlapping residues occur within important structural/functional features of the respective antigens. This was shown to be true for linear (polyclonal and mAbs) and discontinuous antibody epitopes (mAbs), as well as both CD4+ and CD8+ epitopes. Furthermore, many of these same overlapping epitopes residues are also recognized in the context of natural infection. However, we acknowledge that antibody and T cell responses represent functionally distinct processes and concede that the data are as yet insufficient to elucidate a true relationship. It may simply be that functionally important antigens are made in abundance and are therefore likely “seen” more frequently by B and T cells. We hope that ultimately it will be feasible to apply this layering approach using subsets of data selected for high stringency (assays/correlates, etc.) to define epitopes/antigens that are “heavy hitters” from an immunological perspective.

Finally, we also gained some insights into B cell epitope prediction, which suggested that future B cell/antibody prediction tools may incorporate the identification of solvent accessibility scores, as well as of a protein’s features of structural significance. Indeed, there are now databases devoted to protein structure that may be useful in this regard (e.g. ProFunc, PDB, UniProt) [49]. Our data support the premise that epitope location (known positives; not merely predicted) is not solely defined by exposure, as we observe that not all exposed residues are epitopes, and that conversely less exposed and moderately buried residues are often part of functional epitopes. Perhaps epitope prediction in the future will benefit from the inclusion of other factors, such as post-translational modification (e.g., glycosylation). Further, we find that functional epitopes tend to cluster, not unexpectedly around sites known to be involved in antigen function and/or activity. Ultimately, it is our hope that this work will provide the basis for further RSV-specific epitope discovery, as well as future investigation into the nature of antigen conformation in immunogenicity in humans.

Supporting Information
S1 Table. This table provides the results summary of all methods reported for all residues (epitopes) considered: conservancy scores, RSA values, as well as ElliPro and Discotope prediction scores.
(XLSX)
Acknowledgments

The gratefully acknowledge the contributions of Drs. Barney S. Graham and Jason S. McLellan in reviewing this manuscript. This work was supported by NIAID contract number HHSN272201200010C.

Author Contributions

Conceived and designed the experiments: KV JP AS. Performed the experiments: KV JP. Analyzed the data: KV JP BP AS. Contributed reagents/materials/analysis tools: KV JP BP AS. Wrote the paper: KV JP AS.

References

1. Stott EJ, Taylor G, Ball LA, Anderson K, Young KK, King AM, et al. Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus. J Virol 1987; 61: 3855–3861. PMID:3316707
2. Bueno SM, González PA, Pacheco R, Leiva ED, Cautivo KM, Tobar HE, et al. Host immunity during RSV pathogenesis. Int Immunopharmacol 2008; 8(10):1320–1329. doi:10.1016/j.intimp.2008.03.012 PMID:18687294
3. Openshaw PJ, Chiu C. Protective and dysregulated T cell immunity in RSV infection. Curr Opin Virol 2013; 3:468–474. doi:10.1016/j.coovi.2013.05.005 PMID:23806514
4. Shaw CA, Claret M, Cooper BW, Dionigi L, Keith P, O’Brien KB, et al. The path to an RSV vaccine. Curr Opin Virol 2013; 3:332–342. doi:10.1016/j.coovi.2013.05.003 PMID:23727193
5. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jenson K, et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Amer J Epidemiol 1969; 89:422–434. PMID:4305198
6. Prince GA, Janse AB, Hemming VG, Murphy BR, Walsh EE, Horswood RL, et al. Enhancement of respiratory syncytial virus pulmonary pathology in cotton rats by prior intramuscular inoculation of formalin-inactivated virus. J Virol 1986; 57:721–728. PMID:2419587
7. Murphy BR, Prince GA, Walsh EE, Kim HW, Parrott RH, Hemming VG, et al. Dissociation between serum neutralizing and glycoprotein antibody responses in infants and children who received inactivated respiratory syncytial virus vaccine. J Clin Microbiol 1986; 24:197–202. PMID:3755730
8. Murphy BR, Walsh EE. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 1988; 26:1595–1597. PMID:2459154
9. Murphy BR, Alling DW, Snyder MH, Walsh EE, Prince GA, Chanock RM, et al. Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection. J Clin Microbiol 1986; 24:894. PMID:3771779
10. Connors M, Kulkarni AB, Firestone CY, Holmes KL, Morse HC 3rd, Sotnikov AV, et al. Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells. J Virol 1992; 66:7444–7451. PMID:1433525
11. Openshaw PJ, Clarke SL, Record FM. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int Immunol 1992; 4:493–500. PMID:1591217
12. Cheon IS, Shim BS, Park SM, Choi Y, Jang JE, Jung DI, et al. Development of Safe and Effective RSV Vaccine by Modified CD4 Epitope in G Protein Core Fragment (GCF). PLoS One 2014; 9:e84269. doi:10.1371/journal.pone.0094269 PMID:24736750
13. Norrby E, Enders-Ruckle G, Meulen V. Differences in the appearance of antibodies to structural components of measles virus after immunization with inactivated and live vaccine. J Infect Dis 1975; 132:262–269. PMID:1159329
14. Norrby E, Gollmar Y. Identification of measles virus-specific hemolysis-inhibiting antibodies separate from hemagglutination-inhibiting antibodies. Infect Immun 1975; 11:231–239. PMID:803467
15. Ada GL, Leung KN, Ertl H. An Analysis of effector T cell generation and function in mice exposed to influenza A or Sendai viruses. Immunol Rev 1981; 58:5–24. PMID:6273293
16. Nencioni L, Volpini G, Peppoloni S, Bugnoli M, de Magistris T, Marsili I, et al. Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment. Infect Immun 1991; 59:625–630. PMID:1702767
17. Pizza M, Fontana MR, Scarlato V, Rappuoli R. Genetic detoxification of bacterial toxins. Methods Mol Med 2003; 87:133–152. PMID: 12958454

18. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the post-fusion conformation reveals preservation of neutralizing epitopes. J Virol 2011; 85 (15):7778–7796. doi: 10.1128/JVI.00555-11 PMID: 21613394

19. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, et al. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 2013; 342(6158):592–598. doi: 10.1126/science.1243283 PMID: 24179220

20. McLellan JS, Ray WC, Peeples ME. Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 2013; 372:83–104. doi: 10.1007/978-3-642-38919-1_4 PMID: 24362685

21. Correia BE, Bates JT, Loomis RJ, Baneyx G, Carrico C, Jardine JG, et al. Proof of principle for epitope-focused vaccine design. Nature 2014; 507:201–206. doi: 10.1038/nature12966 PMID: 24499818

22. Hall CB, Walsh EE, Long CE, Schnabel KC. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 1991; 163(4):693–698. PMID: 2010624

23. González-Reyes L, Ruiz-Argüello MB, García-Barreno B, Calder L, López JA, Albar JP, et al. Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion. Proc Natl Acad Sci USA 2001; 98(17):9859–9864. PMID: 11493675

24. Zimmer G, Bossow S, Kolesnikova L, Hinz M, Neubert WJ, Herrler G. A chimeric respiratory syncytial virus fusion protein functionally replaces the F and HN glycoproteins in recombinant Sendai virus. J Virol 2005; 79(16):10467–10477. PMID: 16051839

25. Lamb RA. Paramyxovirus fusion: a hypothesis for changes. Virology 1993; 197(1):1–11. PMID: 8212546

26. Magro M, Mas V, Chappell K, Vázquez M, Cano O, Luque D, et al. Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention. Proc Natl Acad Sci USA 2012; 109(8):3089–3094. doi: 10.1073/pnas.1115941109 PMID: 22323598

27. Corti D, Bianchi S, Vanzetta F, Minola A, Perez L, Agatic G, et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 2013; 501(7467):439–443. doi: 10.1038/ nature12442 PMID: 23955151

28. McLellan JS, Chen M, Chang JS, Yang Y, Kim A, Graham BS, et al. Structure of a major antigenic site on the respiratory syncytial virus fusion glycoprotein in complex with neutralizing antibody 101F. J Virol 2010; 84(23):12236–12244. doi: 10.1128/JVI.01579-10 PMID: 20881049

29. Ponomarenko JV, Bui H, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics 2008; 9:514. doi: 10.1186/1471-2105-9-514 PMID: 19055730

30. Andersen PH, Nielsen M, Lund O. Prediction of residues in discontinuous B cell epitopes using protein 3D structures. Protein Science 2006; 15:2558–2567. PMID: 17001032

31. Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol 2012; 8(12):e1002829. doi: 10.1371/ journal.pcbi.1002829 PMID: 23300419

32. Hubbard SJ, Thornton JM. (1993) ‘NACCESS’, Computer Program, Department of Biochemistry and Molecular Biology, University College London.

33. Glaser F, Pupko T, Paz I, Bell RE, Bechor-Shental D, Martz E, et al. ConSurf: identification of functional regions in proteins by surface-mapping of phylogenetic information. Bioinformatics 2003; 19:163–164. PMID: 12499312

34. Kim Y, Vaughan K, Greenbaum J, Peters B, Law M, Sette A. A meta-analysis of the existing knowledge of immunoreactivity against hepatitis C virus (HCV). PLoS One 2012; 7(5):e38028. doi: 10.1371/ journal.pone.0038028 PMID: 22675428

35. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med. 2010; 16(1):123–128. doi: 10.1038/nm.2071 PMID: 20023635

36. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, et al. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 1993; 329(21):1524–1530. PMID: 8413475

37. Zhu O, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, et al. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis 2011; 203:674–682. doi: 10.1093/infdis/jiq100 PMID: 21208913
38. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102:531–537. PMID:9738173

39. Arbiza J, Taylor G, López JA, Furze J, Wyld S, Whyte P, et al. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 1992; 73:2225–2234. PMID: 1383404

40. López JA, Bustos R, Orvell C, Berois M, Arbiza J, García-Barreno B, et al. Antigenic structure of human respiratory syncytial virus fusion glycoprotein. J Virol 1998; 72(8):6922–6928. PMID: 9658147

41. López JA, Peñas C, García-Barreno B, Melero JA, Portela A. Location of a highly conserved neutralizing epitope in the F glycoprotein of human respiratory syncytial virus. J Virol 1990; 64(2):927–930. PMID: 1688629

42. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, et al. Structural basis for immunization with post-fusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci USA 2011; 108(23):9619–9624. doi: 10.1073/pnas.1106536108 PMID: 21586636

43. Colman PM, Lawrence MC. The structural biology of type I viral membrane fusion. Nat Rev Mol Cell Biol 2003; 4(4):309–319. PMID: 12671653

44. Collins PL, Feams R, Graham BS. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 2013; 372:3–38. doi: 10.1007/978-3-642-38919-1_1 PMID: 24362682

45. Christiaansen AF, Knudson CJ, Weiss KA, Varga SM. The CD4 T cell response to respiratory syncytial virus infection. Immunol Res 2014; 59:109–117. doi: 10.1007/s12026-014-8540-1 PMID: 24838148

46. Anderson R, Huang Y, Langley JM. Prospects for defined epitope vaccines for respiratory syncytial virus. Future Microbiol 2010; 5(4):585–602. doi: 10.2217/fmb.10.22 PMID: 20353300

47. Graham BS, Anderson LJ. Challenges and opportunities for respiratory syncytial virus vaccines. Curr Top Microbiol Immunol 2013; 372:391–404. doi: 10.1007/978-3-642-38919-1_20 PMID: 24362701

48. Sakurai H, Williamson RA, Crowe JE, Beeler JA, Poignard P, Bastidas et al. Human antibody responses to mature and immature forms of viral envelope in respiratory syncytial virus infection: significance for subunit vaccines. J Virol. 1999; 73(4):2956–2962. PMID: 10074145

49. Apweiler R, Armstrong R, Bairoch A, Cornish-Bowden A, Halling PJ, Hofmeyr JH, et al. A large-scale protein-function database. Nat Chem Biol 2010; 6(11):785. doi: 10.1038/nchembio.460 PMID: 20956966